Analysis of the proteasome activity and the turnover of the serotonin receptor 2B (HTR2B) in human uveal melanoma.

Uveal melanoma (UM), although a very rare disease, remains a particularly aggressive type of cancer as near 50% of the UM presenting patients will also develop liver metastases within 15 years from the initial diagnostic. One of the most reliable predictive markers of UM at risk of evolving toward the formation of liver lesions is an abnormally elevated level of expression of the transcript encoding the 5-Hydroxytryptamine (serotonin) receptor 2B (HTR2B). In our previous study, we demonstrated that transcription of the HTR2B gene was under the regulatory influences of two transcription factors (TFs), NFI and RUNX1. However, the action of these TFs was insufficient to explain the elevated level of the HTR2B protein in metastatic UM cells or the discrepancies we observed between its expression at the transcriptional and protein levels, therefore suggesting that additional post-translational modifications may also contribute to the altered expression of HTR2B in UM cells. In the present study, we investigated whether the turnover of HTR2B by the proteasome could account at least in part for its deregulated expression. Microarray analyses performed with UM cell lines derived from both non-metastatic and metastatic UM primary tumors revealed important alterations in the expression of some of the transcripts encoding both the E3 ubiquitin ligases and the various subunits of the proteasome, and these modifications were further exacerbated by cell passaging in culture. These alterations also correlated with significant changes in the enzymatic activity of the proteasome. However, the highest proteasome activity and amount of ubiquitinated HTR2B observed in the metastatic T142 cell line, as revealed by immunoprecipitation of ubiquitinated proteins and Western blotting using the HTR2B antibody, apparently had little impact on the total content of HTR2B protein. This contrasts with the near total disappearance of this receptor in the non-metastatic T108 cell line. Our study therefore suggests that the inability of the proteasome to degrade HTR2B in metastatic UM cells might rely on an increased stability of the ubiquitinated receptor in these cells.